BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » CAR-T Financing Frenzy: $100 Billion in Market Cap by CAR-T Companies
CAR-T Financing

CAR-T Financing Frenzy: $100 Billion in Market Cap by CAR-T Companies

February 19, 2021 By Cade Hildreth (CEO) Leave a Comment

CAR-T funding is on the rise. At first the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus and Breyanzi have reached the marketplace and created a CAR-T funding craze. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine.

Discover class-defining bioproduction tools.

In total, financing rounds by CAR-T companies are approaching a total value of $4 billion, while CAR-T industry partnerships contribute another $2 billion.

M&A activity has been even more aggressive, with Celgene snagging Juno Therapeutics for $9 billion in 2018 and Bristol-Myers Squibb (BMS) acquiring Celgene for $74B by 2019. Gilead’s acquisition of Kite Pharma for $11.9 billion also made waves, as have other M&A transactions such as Astellas Pharma’s acquisition of Xyphos Biosciences and its CAR-T technology for $665 million.

In aggregate, there has been nearly $100 billion of market capitalization from CAR-T companies within recent years. Ranging from small start-ups to billion dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.

RoosterCollect EV Pro

To track these industry events, BioInformant has released a 56-page CAR-T cell market brief. It summarizes all types of investments flowing into CAR-T companies worldwide, including financing rounds, IPOs, M&A transactions, co-development agreements, and strategic partnerships.

It also profiles 100+ market competitors that are developing CAR-T technologies.

It features the following information for the CAR-T industry:

  • Financing Rounds
  • IPOs
  • Asset Agreements
  • Strategic Partnerships
  • M&A Transactions
  • Companies Profiles for 100+ CAR-T Competitors

You can use it to:

  1. Quantify CAR-T industry investments
  2. Identify well-capitalized companies
  3. Scout potential partnerships and alliances
  4. Understand partnerships and co-development programs for CAR-T technologies
  5. Identify M&A activity within the CAR-T industry

While this research was originally compiled for our own use, with the recent frenzy of CAR-T funding, more and more clients have been requesting access to it. Would you benefit from knowing all CAR-T industry investments and transactions worldwide?

For a limited-time only, you can access this 56-page report for only $97 (50% off). Remember to act fast, because this offer expires soon!

5 / 5 ( 5 votes )

Filed Under: CAR-T

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Alternate Ocean GCBC

Alternate Ocean Offers to Acquire Largest Cord Blood Bank in China (GCBC) for $5/Share

Reelabs, cord blood banking India

ReeLabs: Cord Blood Banking in India (Population 1.4 Billion)

iPSC-derived therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2021

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.